An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 Trial.

ABSTRACT:

Background

No previous studies have evaluated the effect of an aspirin-free strategy for patients undergoing staged percutaneous coronary intervention (PCI).

Methods and results

We conducted a post hoc subgroup analysis in patients undergoing staged PCI within 1 month in STOPDAPT-3 (n=6,002), which randomly compared prasugrel monotherapy with dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome or high bleeding risk. The co-primary endpoints were major bleeding (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) at 1 month. There were 814 patients undergoing staged PCI within 1 month (no-aspirin group, n=401; DAPT group, n=413). The med

SUBMITTER: Yamamoto K 

PROVIDER: S-EPMC12148353 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature